Climbing stairs
At home, at work, or anywhere the elevator starts looking easier.
If osteoarthritis knee pain is making it harder to move, stay active, or enjoy the moments that matter, Reviscon® Mono 2.0% may help.
Ask your healthcare provider whether Reviscon® Mono 2.0% is right for you.
Reviscon® Mono 2.0% is a single-injection hyaluronic acid treatment from Germany designed to help cushion and lubricate osteoarthritic joints for lasting relief. Talk with your healthcare provider to see whether Reviscon® Mono 2.0% is right for you.
Knee pain rarely changes everything at once. It starts showing up in the routines that used to feel automatic.
Those everyday changes are often the clearest reason to ask whether another option is worth discussing.
At home, at work, or anywhere the elevator starts looking easier.
Parking, lifting, loading, and the trip back into the house.
What used to be automatic becomes something to plan around.
That first step after a long drive tells you a lot.
If you are comparing options for knee OA, it helps to understand not only what Reviscon® Mono 2.0% is used for, but what is worth asking about in its formulation.
This keeps the education grounded in what most patients want to know: how it relates to pain, mobility, treatment fit, and the kind of conversation they want to have with their healthcare professional.
Reviscon® Mono 2.0% is a linear, non-cross-linked hyaluronic acid option. Hyaluronic acid is a substance naturally found in healthy joints, where it helps with lubrication and shock absorption. Because it is not chemically cross-linked, it may have a lower likelihood of post-injection inflammation compared with cross-linked alternatives.
For people with OA knee pain, Reviscon® Mono 2.0% is used to help reduce pain and stiffness and improve mobility.
It offers a treatment conversation that is distinct from steroids, opioids, or day-to-day oral pain medication.
Reviscon® Mono 2.0% is administered directly into the knee joint by a qualified healthcare professional, and relief may last up to six months.
A few practical questions covering fit, timing, treatment, and recovery.
Reviscon® Mono 2.0% is a hyaluronic acid viscosupplement used to help reduce knee osteoarthritis pain and stiffness and improve mobility.
For patients, that means it is an injection-based option to discuss when knee OA is affecting comfort, movement, and daily life. Health Canada lists Reviscon® Mono 2.0% as an active Class III medical device under Licence No. 110891.
Reviscon® Mono 2.0% may be a relevant treatment to discuss with your healthcare professional if knee osteoarthritis pain, stiffness, or reduced mobility is affecting your daily life.
It may be a particularly useful conversation if:
A qualified healthcare professional must assess your knee OA, medical history, symptoms, and treatment goals before deciding whether Reviscon® Mono 2.0% is appropriate for you.
Reviscon® Mono 2.0% is administered directly into the knee joint by a qualified healthcare professional. This type of injection is called an intra-articular injection, meaning the treatment is placed into the joint space.
Reviscon® Mono 2.0% is supplied as a 2.4 mL single-use glass syringe containing 20.0 mg/mL sodium hyaluronate. It is designed as a single-injection viscosupplement.
Improvement is usually gradual. Hyaluronic acid injections are not typically positioned as same-day numbing treatments. They are intended to support joint lubrication and function over time.
Some patients notice improvement over the following weeks. Your healthcare professional can help set expectations based on your knee, symptoms, activity level, and osteoarthritis severity, including what to expect after treatment and when to follow up.
Response varies from person to person. Viscosupplementation injections can provide relief for an average of six months, but results depend on the individual, the affected joint, osteoarthritis severity, activity level, and treatment history.
Your healthcare professional can help you understand what duration of relief is realistic for your situation and whether repeat treatment should be considered. Arthritis Society Canada notes that viscosupplementation is not routinely recommended for all osteoarthritis patients because benefits, risks, and costs need to be weighed carefully.
Reviscon® Mono 2.0% is steroid-free and non-opioid. It is a hyaluronic acid viscosupplement, not a corticosteroid injection and not an oral pain medication.
It is also a linear, non-cross-linked hyaluronic acid option. Hyaluronic acid is similar to a substance naturally found in joints, where it helps with lubrication and shock absorption, and the non-cross-linked structure may have a lower likelihood of post-injection inflammation compared with cross-linked alternatives.
Bring a short list of questions to the appointment so the conversation stays focused on pain, movement, and daily life.
go.reviscon.ca/oa · For informational purposes only.
Start the conversation prepared
Bring the guide to focus your questions on goals, expectations, and next steps.
We use Google Analytics 4 and Google Ads conversion measurement to understand traffic and whether campaigns lead to guide downloads or contact requests. This site is not used for remarketing or ad personalization, and we do not send your form details to Google.Learn more